MX2024004525A - Proteinas modificadas y degradadores de proteinas. - Google Patents
Proteinas modificadas y degradadores de proteinas.Info
- Publication number
- MX2024004525A MX2024004525A MX2024004525A MX2024004525A MX2024004525A MX 2024004525 A MX2024004525 A MX 2024004525A MX 2024004525 A MX2024004525 A MX 2024004525A MX 2024004525 A MX2024004525 A MX 2024004525A MX 2024004525 A MX2024004525 A MX 2024004525A
- Authority
- MX
- Mexico
- Prior art keywords
- protein
- degradators
- modified proteins
- binding
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021123848 | 2021-10-14 | ||
| CN2021133363 | 2021-11-26 | ||
| PCT/CN2022/125080 WO2023061440A1 (en) | 2021-10-14 | 2022-10-13 | Modified proteins and protein degraders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024004525A true MX2024004525A (es) | 2024-05-24 |
Family
ID=85987275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024004525A MX2024004525A (es) | 2021-10-14 | 2022-10-13 | Proteinas modificadas y degradadores de proteinas. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250235543A1 (enExample) |
| EP (1) | EP4416145A1 (enExample) |
| JP (1) | JP2024537394A (enExample) |
| CN (1) | CN118451078A (enExample) |
| AU (1) | AU2022362494A1 (enExample) |
| CA (1) | CA3234615A1 (enExample) |
| IL (1) | IL312013A (enExample) |
| MX (1) | MX2024004525A (enExample) |
| WO (1) | WO2023061440A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022271290A1 (en) | 2021-05-07 | 2023-11-23 | Kymera Therapeutics, Inc. | Cdk2 degraders and uses thereof |
| US20260092062A1 (en) * | 2022-09-26 | 2026-04-02 | Rectify Pharmaceuticals, Inc. | Pyridine carboxamide compounds and their use in treating medical conditions |
| CN121005703A (zh) * | 2024-05-24 | 2025-11-25 | 中国科学院广州生物医药与健康研究院 | 一种酰胺吲嗪类化合物及其制备方法和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017185031A1 (en) * | 2016-04-22 | 2017-10-26 | Dana-Farber Cancer Institute, Inc. | Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use |
| CN112533918A (zh) * | 2018-06-13 | 2021-03-19 | 安菲斯塔治疗有限责任公司 | 用于靶向Rpn11的双功能分子 |
| WO2020092662A1 (en) * | 2018-11-02 | 2020-05-07 | The Wistar Institute Of Anatomy And Biology | Proteolysis-targeting chimeras |
| WO2020173440A1 (en) * | 2019-02-27 | 2020-09-03 | Cullgen (Shanghai), Inc. | Cyclic-amp response element binding protein (cbp) and/or adenoviral e1a binding protein of 300 kda (p300) degradation compounds and methods of use |
| WO2020206608A1 (en) * | 2019-04-09 | 2020-10-15 | Ranok Therapeutics (Hangzhou) Co., Ltd. | Methods and compositions for targeted protein degradation |
| AU2020263390B2 (en) * | 2019-04-23 | 2026-01-08 | Dana-Farber Cancer Institute, Inc. | Degraders of cyclin-dependent kinase 12 (CDK12) and uses thereof |
| CN112409376A (zh) * | 2019-08-20 | 2021-02-26 | 华东师范大学 | 一种基于dcaf15的蛋白降解靶向嵌合体及其制备方法和应用 |
| TW202126638A (zh) * | 2019-09-30 | 2021-07-16 | 日商協和麒麟股份有限公司 | Bet分解劑 |
| JP2023529099A (ja) * | 2020-05-28 | 2023-07-07 | クルゲン（シャンハイ），インク． | 修飾タンパク質およびタンパク質分解誘導薬 |
-
2022
- 2022-10-13 MX MX2024004525A patent/MX2024004525A/es unknown
- 2022-10-13 US US18/700,898 patent/US20250235543A1/en active Pending
- 2022-10-13 IL IL312013A patent/IL312013A/en unknown
- 2022-10-13 WO PCT/CN2022/125080 patent/WO2023061440A1/en not_active Ceased
- 2022-10-13 CN CN202280082680.9A patent/CN118451078A/zh active Pending
- 2022-10-13 EP EP22880376.3A patent/EP4416145A1/en active Pending
- 2022-10-13 JP JP2024522487A patent/JP2024537394A/ja active Pending
- 2022-10-13 CA CA3234615A patent/CA3234615A1/en active Pending
- 2022-10-13 AU AU2022362494A patent/AU2022362494A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250235543A1 (en) | 2025-07-24 |
| IL312013A (en) | 2024-06-01 |
| AU2022362494A1 (en) | 2024-05-23 |
| EP4416145A1 (en) | 2024-08-21 |
| WO2023061440A1 (en) | 2023-04-20 |
| CN118451078A (zh) | 2024-08-06 |
| CA3234615A1 (en) | 2023-04-20 |
| JP2024537394A (ja) | 2024-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125429T1 (el) | Μουτεϊνες ιντερλευκινης-21 και μεθοδοι θεραπευτικης αγωγης | |
| WO2019136180A3 (en) | Heteroduplex nucleic acid molecules and uses thereof | |
| CY1121687T1 (el) | Αλληλουχιες αμινοξεων που κατευθυνονται εναντι των πρωτεϊνων φακελου ενος ioy και πολυπεπτιδια που τις περιεχουν για τη θεραπευτικη αντιμετωπιση ιικων νoσων | |
| BR112019023855A2 (pt) | proteínas de ligação à mesotelina | |
| CY1118901T1 (el) | Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις | |
| CY1117161T1 (el) | Βελτιωμενοι κυτταροτοξικοι παραγοντες οι οποιοι περιεχουν νεα μεϋτανσινοειδη | |
| DE602004031714D1 (de) | Anthracyclin-anti-cd74-antikörperkonjugate | |
| EP2453908A4 (en) | BIFUNCTIONAL STACKED POLYPEPTIDES AND USES THEREOF | |
| MX2022003217A (es) | Conjugados terapeuticos. | |
| CY1119412T1 (el) | Μεθοδοι για την αξιολογηση μιας ανοσοαποκρισης σε εναν θεραπευτικο παραγοντα | |
| CL2023000554A1 (es) | Proteínas diseñadas y métodos de uso de las mismas. | |
| BRPI0508068A (pt) | moléculas de ácido nucléico isoladas, vetor compreendendo as mesmas, polipeptìdeos isolados e composições compreendendo os mesmos | |
| BR112013004579A2 (pt) | proteína de ligação à mmp9, ácido nucleico, vetor, célula, composição farmacêutica e seu uso bem como método de detecção da expressão mmp9 | |
| CY1114851T1 (el) | Il-1βητα δεσμευτικα αντισωματα και θραυσματα αυτων | |
| CY1116413T1 (el) | Καινοφανη πληρως-ανθρωπινα μονοκλωνικα αντισωματα anti-vap-1 | |
| BR112022019689A2 (pt) | Citocinas il-2 mascaradas, citocina mascarada, produtos de clivagem, ácido nucleico, vetor, célula hospedeira, composição, kit e métodos de produção de uma citocina il-2 mascarada e de tratamento ou prevenção de câncer | |
| JOP20210159A1 (ar) | أجسام مضادة لـ pmel17 ومترافقات منها | |
| BR112023023650A2 (pt) | Composições e métodos relacionados a anticorpos ativados por tumores direcionados a egfr e antígenos de células efetoras | |
| CL2023001667A1 (es) | Composiciones de agentes de unión a antígenos de guanilato ciclasa c (gcc) y métodos de uso de estos | |
| BR112023022315A2 (pt) | Quimeras direcionadas à desubiquitinase e métodos relacionados | |
| MX2024006205A (es) | Composiciones que comprenden agentes de unión multiespecíficos potenciados para una respuesta inmunitaria. | |
| MX2021010577A (es) | Compuestos de union a pd-l1 multivalentes para tratar cancer. | |
| ECSP11010772A (es) | Inhibidor de infección | |
| AR112777A1 (es) | Muteínas de interleucina 21 y métodos de tratamiento | |
| AR120015A1 (es) | Conjugados terapéuticos |